

# Diagnosis and Treatment of Cervical Cancer: A Review

Ashlesha Deverakonda<sup>1\*</sup> and Neha Gupta<sup>2</sup>

<sup>1</sup>Department of Pharmaceutical Analysis and Quality Assurance, Malla Reddy College of Pharmacy, Hyderabad, India

<sup>2</sup>Amity Institute of Biotechnology, Amity University Uttar Pradesh (AUUP), Noida, India

## Review Article

Received: 27/08/2016  
Revised: 30/08/2016  
Accepted: 6/09/2016

### \*For Correspondence

Department of Pharmaceutical Analysis and Quality Assurance, Malla Reddy College of Pharmacy, Hyderabad, India

**Keywords:** Human papillomavirus, Oral contraceptives, Chemotherapy, Hysterectomy

### E-mail:

[Ashlesha.sweety4@gmail.com](mailto:Ashlesha.sweety4@gmail.com)

## ABSTRACT

Cervical cancer is a type of malignancy emerging from cervix. This is a type of a cancer seen in women having regular oral contraceptives, infected with papillomavirus, having multiple pregnancies or by sexual relation with one or more men. This type of cancer can be detected by various symptoms like excessive bleeding through vagina after sexual contact or through metastases. It can be treated with cisplatin in chemotherapy, trachelectomy, hysterectomy and the kind of the treatment depends on the stage of the cancer and its severity.

## INTRODUCTION

Cervical growth is a malignancy emerging from the cervix. It is because of the irregular development of cells that can attack or spread to different parts of the body. From the get-go, commonly no indications are seen. Later indications may incorporate unusual vaginal bleeding, pelvic pain, or torment amid sex. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer [1,2].

Human papillomavirus (HPV) contamination has all the earmarks of being required in the improvement of more than 90% of cases; the vast majority who have had HPV diseases, be that as it may, don't create cervical growth. Other danger elements incorporate smoking, a powerless resistant framework, conception prevention pills, beginning sex at a youthful age, and having numerous sexual accomplices, yet these are less essential. Cervical disease regularly creates from precancerous changes more than 10 to 20 years. Around 90% of cervical malignancy cases are squamous cell carcinomas, 10% are adenocarcinoma, and a little number are different sorts. Determination is regularly by cervical screening took after by a biopsy. Medicinal imaging is then done to figure out if or not the growth has spread [2-4].

HPV antibodies ensure against somewhere around two and seven high-chance strains of this group of infections and may avert up to 90% of cervical tumors. As a danger of disease still exists, rules prescribe proceeding with normal Pap smears. Different techniques for counteractive action include: having few or no sexual accomplices and the utilization of condoms [5]. Cervical growth screening utilizing the Pap smear or acidic corrosive can distinguish precancerous changes which when treated can keep the improvement of malignancy. Treatment of cervical disease may comprise of some blend of surgery, chemotherapy, and radiotherapy. Five year survival rates in the United States are 68%. Results, in any case, depend especially on how early the malignancy is recognized.

Around the world, cervical malignancy is both the fourth-most normal reason for growth and the fourth-most regular reason for death from tumor in ladies. In 2012, an expected 528,000 instances of cervical growth happened, with 266,000 deaths. This is around 8% of the aggregate cases and aggregate deaths from tumor. Around 70% of cervical growths happen in creating nations. In low-pay nations, it is the most widely recognized reason for disease demise. In created nations, the far reaching utilization of cervical screening programs has drastically decreased rates of cervical disease [6,7].

### SIGNS AND SYMPTOMS

The early phases of cervical malignancy might be totally free of side effects <sup>[8]</sup>. Vaginal bleeding, contact bleeding (one most normal structure being seeping after sex), or (once in a while) a vaginal mass may show the nearness of danger. Likewise, direct agony amid sex and vaginal release are side effects of cervical growth. In cutting edge ailment, metastases might be available in the midriff, lungs, or somewhere else <sup>[9,10]</sup>.

Side effects of cutting edge cervical disease may include: loss of voracity, weight reduction, weakness, pelvic torment, back torment, leg torment, swollen legs, overwhelming vaginal drying, bone cracks, and/or (seldom) spillage of pee or dung from the vagina. Seeping subsequent to douching or after a pelvic exam is a typical side effect of cervical malignancy.

### CAUSES

Contamination with a few sorts of HPV is the most serious danger element for cervical tumor, trailed by smoking. HIV disease is likewise a danger variable. Not the majority of the reasons for cervical malignancy are known, be that as it may, and a few other contributing variables have been ensnared.

#### Human Papillomavirus

Human papillomavirus sorts 16 and 18 are the reason for 75% of cervical malignancy cases all inclusive, while 31 and 45 are the reasons for another 10%.

Ladies who have numerous sexual accomplices (or who engage in sexual relations with men who have had numerous different accomplices) have a more serious danger.

Of the 150-200 sorts of HPV referred to, 15 are delegated high-chance sorts (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), three as likely high-hazard (26, 53, and 66), and 12 as generally safe (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108).

Genital warts, which are a type of amiable tumor of epithelial cells, are additionally brought on by different strains of HPV. Be that as it may, these serotypes are generally not identified with cervical malignancy. It is basic to have different strains in the meantime, including those that can bring about cervical growth alongside those that cause warts.

Disease with HPV is for the most part accepted to be required for cervical tumor to happen.

#### Smoking

Cigarette smoking, both dynamic and uninvolved, expands the danger of cervical malignancy. Among HPV-contaminated ladies, present and previous smokers have approximately a few times the rate of obtrusive growth. Inactive smoking is likewise connected with expanded danger, however to a lesser degree <sup>[11]</sup>.

Smoking has likewise been connected to the improvement of cervical disease. Smoking can build the danger in ladies a couple of various ways, which can be by immediate and backhanded strategies for affecting cervical growth. An immediate method for getting this tumor is a smoker has a higher shot of CIN3 happening which has the capability of shaping cervical malignancy. At the point when CIN3 sores lead to disease, the majority of them have the help of the HPV infection, yet that is not generally the situation, which is the reason it can be viewed as an immediate connection to cervical malignancy. Overwhelming smoking and long term smoking appear to have all the more a danger of getting the CIN3 sores than lighter smoking or not smoking by any means. Albeit smoking has been connected to cervical tumor, it helps in the advancement of HPV which is the main source of this sort of malignancy <sup>[12]</sup>. Likewise, not just does it help in the advancement of HPV, additionally if the lady is now HPV-positive; she is at a considerably more prominent probability of contracting cervical malignancy.

**Oral contraceptives:** Long term utilization of oral contraceptives is connected with expanded danger of cervical growth. Ladies who have utilized oral contraceptives for 5 to 9 years have around three times the frequency of obtrusive growth, and the individuals who utilized them for a long time or more have around four times the danger <sup>[13]</sup>.

#### Multiple Pregnancies

Having numerous pregnancies is connected with an expanded danger of cervical tumor <sup>[14]</sup>. Among HPV-contaminated ladies, the individuals who have had seven or all the more full-term pregnancies have around four times the danger of growth contrasted and ladies without any pregnancies, and a few times the danger of ladies who have had maybe a couple full-term pregnancies.

### DIAGNOSIS

#### Biopsy

The Pap smear can be utilized as a screening test, however is false negative in up to half of instances of cervical tumor. Affirmation of the analysis of cervical malignancy or precancer requires a biopsy of the cervix. This is frequently done through colposcopy, an amplified visual assessment of the cervix supported by utilizing weakened acidic corrosive (e.g. vinegar) answer for highlight irregular cells on the surface of the cervix. Therapeutic gadgets utilized for biopsy of the cervix incorporate punch forceps, SpiraBrush CX, SoftBiopsy, or Soft-ECC <sup>[15]</sup>.

Colposcopy impression, the appraisal of malady seriousness in light of the visual review, frames part of the conclusion <sup>[16]</sup>.

Further indicative and treatment strategies are loop electrical excision procedure and conization, in which the inward coating of the cervix is expelled to be inspected pathologically. These are done if the biopsy affirms serious cervical intraepithelial neoplasia <sup>[17]</sup>.

This vast squamous carcinoma (base of picture) has wrecked the cervix and attacked the lower uterine section. The uterus likewise has a round leiomyoma up higher.

Regularly before the biopsy, the specialist requests restorative imaging to discount different reasons for lady's side effects. Imaging modalities such as ultrasound, CT output and MRI have been utilized to search for exchanging malady, spread of tumor and impact on nearby structures. Regularly, they show up as heterogeneous mass in the cervix <sup>[18]</sup>.

#### Cancer Subtypes

Histologic subtypes of obtrusive cervical carcinoma incorporate the accompanying: Though squamous cell carcinoma is the cervical growth with the most frequency, the rate of adenocarcinoma of the cervix has been expanding in late decades <sup>[19]</sup>.

- squamous cell carcinoma (around 80-85% (citation needed))
- adenocarcinoma (around 15% of cervical tumors in the UK <sup>[38]</sup>)
- adenosquamous carcinoma
- small cell carcinoma
- neuroendocrine tumor
- glassy cell carcinoma
- villoglandular adenocarcinoma

Noncarcinoma malignancies which can once in a while happen in the cervix incorporate melanoma and lymphoma. The FIGO stage does not incorporate lymph hub contribution as opposed to the TNM arranging for most different growths.

For cases treated surgically, data acquired from the pathologist can be utilized as a part of relegating a different pathologic stage however is not to supplant the first clinical stage.

**Stage 0:** The carcinoma is restricted to the surface layer (cells coating) of the cervix. Likewise called carcinoma in situ (CIS).

**Stage I:** The carcinoma has become further into the cervix, yet has not spread past it (expansion to the corpus would be slighted). Stage I is subdivided as takes after:

IA Invasive carcinoma which can be analyzed just by microscopy, with most profound attack <5 mm and the biggest expansion <7 mm

IA-1 Measured stromal attack of <3.0 mm top to bottom and expansion of <7.0 mm

IA-2 Measured stromal attack of >3.0 mm and not >5.0 mm with an expansion of not >7.0 mm

IB Clinically unmistakable sores constrained to the cervix uteri or pre-clinical tumors more noteworthy than stage IA

IB-1 Clinically unmistakable sore <4.0 cm in most noteworthy measurement

IB-2 Clinically unmistakable sore >4.0 cm in most noteworthy measurement

**Stage II:** Cervical carcinoma attacks past the uterus, however not to the pelvic divider or to the lower third of the vagina

IIA Without parametrial intrusion

IIA-1 Clinically unmistakable sore <4.0 cm in most noteworthy measurement

IIA-2 Clinically unmistakable sore >4.0 cm in most noteworthy measurement

IIB With clear parametrial attack

**Stage III:** The tumor reaches out to the pelvic divider and/or includes bring down third of the vagina and/or causes hydronephrosis or non-working kidney [20].

IIIA Tumor includes bring down third of the vagina, with no expansion to the pelvic divider

IIIB Extension to the pelvic divider and/or hydronephrosis or non-working kidney

**Stage IV:** The carcinoma has reached out past the genuine pelvis or has included (biopsy demonstrated) the mucosa of the bladder or rectum [21]. A bullous oedema, in that capacity, does not allow a case to be designated to Stage IV

IVA Spread of the development to adjoining organs

IVB Spread to removed organs

## PREVENTION

### Screening

Checking the cervix by the Papanicolaou test, or Pap smear, for cervical disease has been credited with drastically decreasing the quantity of instances of and mortality from cervical tumor in created nations. Pap smear screening at regular intervals with fitting follow-up can decrease cervical disease rate up to 80% [22-25]. Unusual results may propose the nearness of precancerous changes, permitting examination and conceivable preventive treatment. The treatment of second rate injuries may antagonistically influence ensuing fruitfulness and pregnancy. Individual solicitations urging ladies to get screened are compelling at improving the probability they will do as such. Instructive materials likewise improve the probability ladies will go for screening, however they are not as successful as solicitations [26-29].

As indicated by the 2010 European rules, the age at which to begin screening ranges somewhere around 20 and 30 years old, "yet specially not before age 25 or 30 years", and relies on upon weight of the illness in the populace and the accessible assets.

In the United States, screening is prescribed to start at age 21, paying little heed to age at which a lady started having intercourse or other danger variables. Pap tests ought to be done like clockwork between the ages of 21 and 65. In ladies beyond 65 years old, screening might be stopped if no unusual screening results were seen inside the past 10 years and no history of CIN 2 or higher exists. HPV inoculation status does not change screening rates. Screening can happen like clockwork between ages 30 and 65 when a mix of cervical cytology screening and HPV testing is utilized and this is preferred. However, it is adequate to screen this age bunch with a Pap spread alone at regular intervals. Screening is not helpful before age 25 as the rate of illness is low. Screening is not gainful in ladies more seasoned than 60 years on the off chance that they have a background marked by negative results [30].

Fluid based cytology is another potential screening technique. In spite of the fact that it was presumably proposed to enhance the exactness of the Pap test, its fundamental favorable position has been to decrease the quantity of lacking smears from around 9% to around 1%. This lessens the need to review ladies for a further spread. The United States Preventive Services Task Force bolsters screening at regular intervals in the individuals who are somewhere around 30 and 65 years when cytology is utilized as a part of mix with HPV testing [31].

Pap smears have not been as viable in creating nations. This is to a limited extent in light of the fact that a number of these nations have a bankrupted social insurance framework, excessively few prepared and talented experts, making it impossible to get and interpret Pap smears, clueless ladies who motivate lost to postliminary, and a protracted pivot time to get results. These substances have brought about the examination of cervical screening approaches that utilization less assets and offer fast results, for example, visual assessment with acidic corrosive or HPV DNA testing [32].

### Barrier protection

Obstruction security and/or spermicidal gel use amid sex diminishes malignancy hazard. Condoms offer insurance against cervical growth. Proof on whether condoms secure against HPV disease is blended, yet they may ensure against genital warts and the forerunners to cervical growth. They additionally give assurance against different STIs, for example, HIV and Chlamydia, which are connected with more serious dangers of creating cervical growth [33,34].

Condoms may likewise be helpful in treating conceivably precancerous changes in the cervix. Presentation to semen seems to expand the danger of precancerous changes (CIN 3), and utilization of condoms causes these progressions to relapse and clears HPV. One study proposes that prostaglandin in semen may fuel the development of cervical and uterine tumours and that influenced ladies may profit by the utilization of condoms [35].

Forbearance likewise forestalls HPV contamination.

### Vaccination

Two HPV antibodies (Gardasil and Cervarix) diminish the danger of malignant or precancerous changes of the cervix and perineum by around 93% and 62%, separately. The antibodies are somewhere around 92% and 100% powerful against HPV 16 and 18 up to no less than 8 years [36-41].

HPV antibodies are commonly given to age 9 to 26 as the immunization is just powerful if given before contamination happens. The immunizations have been appeared to be powerful for no less than 4 to 6 years, and they are accepted to be compelling for more; be that as it may, the term of adequacy and whether a supporter will be required is obscure [42]. The high cost of this antibody has been a reason for concern. A few nations have considered (or are thinking about) projects to subsidize HPV inoculation.

Since 2010, young ladies in Japan have been qualified to get the cervical disease immunization for free [60]. In June 2013, the Japanese Ministry of Health, Labor and Welfare mandated that, before overseeing the antibody, therapeutic foundations must educate ladies that the Ministry does not prescribe it. In any case, the immunization is still accessible at no expense to Japanese ladies who acknowledge the inoculation [43-45].

### Nutrition

Vitamin A is connected with a lower hazard as are vitamin B12, vitamin C, vitamin E, and beta-carotene [46-50].

## TREATMENT

The treatment of cervical disease differs around the world, to a great extent because of access to specialists gifted in radical pelvic surgery, and the rise of "fertility-sparing therapy" in created countries [51]. Since cervical malignancies are radiosensitive, radiation might be utilized as a part of all phases where surgical alternatives don't exist.

Microinvasive malignancy (stage IA) might be dealt with by hysterectomy (expulsion of the entire uterus including part of the vagina). For stage IA2, the lymph hubs are evacuated, too. Options incorporate nearby surgical methods, for example, a circle electrical extraction strategy or cone biopsy. For 1A1 infection, a cone biopsy (cervical conization) is viewed as therapeutic [52-56].

In the event that a cone biopsy does not deliver clear edges (discoveries on biopsy demonstrating that the tumor is encompassed by malignancy free tissue, recommending the majority of the tumor is expelled), one more conceivable treatment choice for ladies who need to protect their ripeness is a trachelectomy. This endeavors to surgically expel the disease while safeguarding the ovaries and uterus, accommodating a more moderate operation than a hysterectomy [57]. It is a practical alternative for those in stage I cervical tumor which has not spread; be that as it may, it is not yet considered a standard of care, as few specialists are talented in this system. Indeed, even the most experienced specialist can't guarantee that a trachelectomy can be performed until after surgical infinitesimal examination, as the degree of the spread of tumor is obscure. On the off chance that the specialist is not ready to infinitesimally affirm clear edges of cervical tissue once the lady is under general anesthesia in the working room, a hysterectomy may in any case be required [58]. This must be done amid the same operation if the lady has given earlier assent. Because of the conceivable danger of growth spread to the lymph hubs in stage 1b diseases and some stage 1a tumours, the specialist may likewise need to expel some lymph hubs from around the uterus for pathologic assessment.

A radical trachelectomy can be performed abdominally or vaginally and conclusions are clashing as to which is better. A radical stomach trachelectomy with lymphadenectomy typically just requires an a few day healing center stay, and most ladies recuperate rapidly (around six weeks). Difficulties are exceptional, in spite of the fact that ladies who can imagine after surgery are defenseless to preterm work and conceivable late unnatural birth cycle. Hold up no less than one year is by and large prescribed before endeavoring to end up pregnant after surgery [59-65]. Repeat in the leftover cervix is extremely uncommon if the tumor has been cleared with the trachelectomy. However, ladies are prescribed to hone watchful anticipation and subsequent consideration including Pap screenings/colposcopy, with biopsies of the rest of the lower uterine section as required (like clockwork for no less than 5 years) to screen for any repeat notwithstanding minimizing any new exposures to HPV through safe sex hones until one is effectively attempting to imagine.

Early stages (IB1 and IIA under 4 cm) can be treated with radical hysterectomy with evacuation of the lymph hubs or radiation treatment. Radiation treatment is given as outer shaft radiotherapy to the pelvis and brachytherapy (inner radiation) [66,67]. Ladies treated with surgery who have high-chance components found on pathologic examination are given radiation treatment with or without chemotherapy to lessen the danger of backslide.

Bigger early-arrange tumors (IB2 and IIA more than 4 cm) might be treated with radiation treatment and cisplatin-based chemotherapy, hysterectomy (which then as a rule requires adjuvant radiation treatment), or cisplatin chemotherapy took after by hysterectomy. At the point when cisplatin is available, it is thought to be the most dynamic single specialist in occasional sicknesses [68-70].

Propelled stage tumors (IIB-IVA) are treated with radiation treatment and cisplatin-based chemotherapy. On June 15, 2006, the US Food and Drug Administration affirmed the utilization of a mix of two chemotherapy drugs, hycamtin and cisplatin, for ladies with late-organize (IVB) cervical disease treatment. Blend treatment has noteworthy danger of neutropenia, frailty, and thrombocytopenia symptoms [71,72].

For surgery to be therapeutic, the whole growth must be expelled with no tumor found at the edges of the evacuated tissue on examination under a magnifying instrument. This methodology is known as exenteration.

### PROGNOSIS

Forecast relies on upon the phase of the malignancy. The possibility of a survival rate around 100% is high for ladies with minuscule types of cervical disease [73]. With treatment, the five-year relative survival rate for the soonest phase of obtrusive cervical tumor is 92%, and the generally speaking (all stages consolidated) five-year survival rate is around 72%. These insights might be enhanced when connected to ladies recently analyzed,

remembering that these results might be incompletely in light of the condition of treatment five years back when the ladies concentrated on were initially analysed [74-78].

With treatment, 80 to 90% of ladies with stage I disease and 60 to 75% of those with stage II tumor are alive 5 years after conclusion. Survival rates reduction to 30 to 40% for ladies with stage III tumor and 15% or less of those with stage IV growth 5 years after analysis [79-85].

As per the International Federation of Gynecology and Obstetrics, survival enhances when radiotherapy is joined with cisplatin-based chemotherapy [85-92].

As the tumor metastasizes to different parts of the body, visualization drops significantly on the grounds that treatment of nearby injuries is for the most part more powerful than entire body medicines, for example, chemotherapy [93].

Interim assessment of the lady after treatment is basic. Intermittent cervical tumor recognized at its most punctual stages may be effectively treated with surgery, radiation, chemotherapy, or a mix of the three. Around 35% of ladies with obtrusive cervical malignancy have tenacious or repetitive sickness after treatment [94].

Normal years of potential life lost from cervical malignancy are 25.3. Around 4,600 ladies were anticipated to pass on in 2001 in the US of cervical tumor, and the yearly rate was 13,000 in 2002 in the US, as figured by SEER. In this manner, the proportion of passings to frequency is around 35.4% [95].

Consistent screening has implied that precancerous changes and early-organize cervical malignancies have been distinguished and treated early. Figures recommend that cervical screening is sparing 5,000 lives every year in the UK by averting cervical tumor [96]. Around 1,000 ladies for every incredible cervical tumor in the UK. The greater part of the Nordic nations has cervical malignancy screening programs set up. Pap smear was coordinated into clinical practice in the Nordic nations in the 1960s [97-100].

### REFERENCES

1. Ali CI, et al. Cervical cancer: a health limiting condition. *Gynecol Obstet.* 2016;6:378.
2. Abate SM. Trends of cervical cancer in ethiopia. *Cervical Cancer.* 2015;1:103.
3. Gavrilesco MM, et al. Minimally invasive surgery: a new approach for uterine cervical cancer. *Journal of Surgery.* 2015;11:93-97
4. Marconi DG. Cervical cancer: state of the art and future directions. *J Nucl Med Radiat Ther.* 2013; 4:156.
5. Gonzalez AD. The achilles heel of cervical cancer: an overlooked target? *J Pharmacogenom Pharmacoproteomics.* 2012;3:e128.
6. Soumya D and Arun Kumar R. A brief assessment on cervical cancer. *J Cancer Sci Ther.* 2011;S17.
7. Myles Z, et al. A profile of the national breast and cervical cancer early detection program (nbccedp) provider network: Results from the year 1 nbccedp survey of program implementation. *Quality in Primary Care.* 2015;23:315-317.
8. El-Moselhy EA, et al. Cervical cancer: sociodemographic and clinical risk factors among adult egyptian females. *Adv Oncol Res Treat.* 2016;1:106.
9. Cesario SK, et al. Abused women at risk for hpv and cervical cancer: Decisions to vaccinate their children. *Clinics Mother Child Health.* 2015;12:194.
10. Irigaray CA et al. A commentary on wnt7a implication in cervical cancer development. *j genet syndr gene ther.* 2015;6:267.
11. Matthews AK, et al. Breast and cervical cancer screening behaviors of african american sexual minority women. *J Gen Pract.* 2013;1:107.
12. Yilmaz MO, et al. Relationship between smoking and female sexual dysfunction. *Andrology.* 2015;4:144.
13. Grant EC. Endometrial cancer with progestin and estrogen oral contraceptives and hormone therapy – a review and analysis of the current data. *J Cancer Clin Trials.* 2016;1:114.
14. Dooley W, et al. A comparison of perinatal outcomes in multiple pregnancies: assisted versus spontaneous conception: a cross-sectional study. *JFIV Reprod Med Genet.* 2016;4:174.
15. Sahli N, et al. Impact of brachytherapy in the treatment of locally advanced cervical cancer: results from a single institution. *Gynecol Obstet.* 2016;6:386.

16. AbdAlla A and Elsadig M. Perception of nursing students towards palliative care of cervical cancer in sudan. *Cervical Cancer*. 2016;1:108.
17. Morris MR. Factors associated with the uptake of cervical cancer screening among women of reproductive age in homabay county, kenya: a case of kanyadhiang sub location. *Clinics Mother Child Health*. 2016;13:232.
18. Cuschieri K and Wentzensen N. Human papillomavirus mrna and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. *Cancer Epidemiol Biomarkers Prev*. 2008;17:2536-2545.
19. Chhabra S, et al. Staging issues in cervical cancer. *Cancer Surg*. 2016;1:105.
20. AbdAllah AAA, et al. Awareness and attitudes of nursing students towards prevention of cervical cancer. *Cervical Cancer*. 2016;1:107.
21. da Fonseca AJ, et al. Cost-effectiveness of primary and secondary prevention strategies for cervical cancer in brazil: A systematic review. *Gynecol Obstet*. 2013;3:169.
22. Sarwar A, et al. Novel benchmark database of digitized and calibrated cervical cells for artificial intelligence based screening of cervical cancer. *Cervical Cancer*. 2016;1:105.
23. Begum S, et al. Mobilising women from a low income community to attend cervical cancer screening camps: insights from a study in an urban slum of mumbai. *Gynecol Obstet*. 2014;4:197.
24. Stuardo V, et al. Low prevalence of cervical cancer screening among hiv-positive women in catalonia (spain). *J AIDS Clinic Res*. 2013;S3:004.
25. Singh S and Badaya S. Factors influencing uptake of cervical cancer screening among women in india: a hospital based pilot study. *J Community Med Health Educ*. 2012;2:157.
26. Döbrössy L, et al. Inequalities in cervical screening practices in europe. *Diversity and Equality in Health and Care*. 2015;12:48-53.
27. Biobaku O, et al. Perception, sources of information and utilization of papanicolaou (pap) smear for cervical cancer screening among female nurses in southwest nigeria. Part 1. *Journal of Prevention & Infection Control*. 2015;1:5.
28. Keshavarzi F, et al. Cervical visual inspection with acetic acid as an alternative screening test for cervical cancer detection. *International Journal of Collaborative Research on Internal Medicine & Public Health*. 2013;5:60-66.
29. Garcia AA. Cervical cancer screening. *Am J Obstet Gynecol*. 2006;155:139-144.
30. Ndikom CM and Ofi BA. Awareness, perception and factors affecting utilization of cervical cancer screening services among women in Ibadan, Nigeria: a qualitative study. *Reprod Health* 2012;9:11.
31. Perkins RB, et al. A community-based education program about cervical cancer improves knowledge and screening behavior in Honduran women. *Rev Panam Salud Publica*. 2007;22:187-193.
32. Saslow D, et al. American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. *J Low Genit Tract Dis*. 2012;16:175-204.
33. Gebru Z, et al. Barriers to cervical cancer screening in Arab Minch town, southern Ethiopia: a qualitative study. *J Community Med Health*. 2016;6:401.
34. Al-Naggar RA and Chen R. Practice and barriers towards cervical cancer screening among university staff at a Malaysian university. *J Community Med Health Educ*. 2012;2:120.
35. Juwita S, et al. Barriers to cardiovascular screening among Malay women in east coast Malaysia. *International Journal of Collaborative Research on Internal Medicine & Public Health*. 2013;5:67-78.
36. Voltyraki EG, et al. Comparative assessment of knowledge regarding the pap test and their receptivity to HPV vaccination between women- health professionals and women of general population, in Greek province areas. *Health Science Journal*. 2012;6:170-181.
37. Fonseca AJ and de Lima Ferreira LC. Systematic review of the cost-effectiveness of the vaccination against hpv in brazil. *Hum Vaccin Immunother*. 2014;10:3484-3490.
38. Natunen K, et al. Cost-effectiveness of hpv-vaccination in medium or low income countries with high cervical cancer incidence – a systematic review. *J Vaccines Vaccin*. 2013;4:172.
39. Liu FW, et al. Cervical cancer and HPV vaccination: knowledge and attitudes of adult women in Lusaka, Zambia. *J Vaccines Vaccin*. 2012;3:138.

40. Jalani FFM, et al. Knowledge, attitude and practice of human papillomavirus (HPV) vaccination among secondary school students in rural areas of Nigeria Sembilan, Malaysia. *International Journal of Collaborative Research on Internal Medicine & Public Health*. 2016;8:420-434.
41. Ahmed M, et al. The use of oncolytic vesicular stomatitis virus in conjunction with natural products for the treatment of cervical cancers. *Adv Tech Biol Med*. 2015;3:133.
42. Uddin MN. Alternative vaccine strategies for cervical cancer. *J Develop Drugs*. 2015;4:e139.
43. Menczer J, et al. A comparison of Israeli Jewish women with genital warts (condilimata acuminata) to cervical cancer patients regarding the presence of selected risk factors. *Gynecol Obstet*. 2013;3:174.
44. Bosquet EG and Mazarico E. Importance of different HPV genotypes in the development of cervical cancer. *J Vaccines Vaccin*. 2012;3:161.
45. Obeidat RA and Saidi SA. Prevalence of high-grade cervical intraepithelial neoplastic (CIN) and cervical cancer in women with postcoital bleeding (PCB) and negative smear: a retrospective study. *Gynecol Obstet*. 2012;2:127.
46. Dadlani K, et al. Assessment of the expression of long noncoding mitochondrial rnas (lncmtRNAs) during cervical cancer progression and cervical carcinoma. *J Cancer Sci Ther*. 2016;8:038-045.
47. Pomerai KW, et al. Knowledge of cervical cancer among Zimbabwean women on anti-retro viral therapy 2012. *J AIDS Clin Res*. 2015;6:495.
48. Malik SN and Shams M. Role of uterine artery embolization in the management of cervical cancer: review article. *J Cancer Sci Ther*. 2012;4:167-169.
49. Malapati R, et al. Late midtrimester pregnancy, advanced bulky cervical cancer, radiation therapy, and physician's moral distress: A management dilemma. *Gynecol Obstetric*. 2012;2:114.
50. Irving ER and Mans DRA. Age and ethnic differences in the occurrence of cervical dysplasia, cervical cancer, and cervical cancer deaths in Suriname. *Translational Biomedicine*. 2015;6:1.
51. Diaz ML. Human papilloma virus: prevention and treatment. *Obstet Gynecol Clin North Am*. 2008;35:199-217.
52. Chen SW, et al. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. *Radiother Oncol*. 2003;67:69-76.
53. Sahli N, et al. Impact of treatment duration on cervical cancer outcomes: results from a single institution. *Gynecol Obstet*. 2016;6:354.
54. Tadesse SK. Preventive mechanisms and treatment of cervical cancer in ethiopia. *Cervical Cancer*. 2015;1:101.
55. Mobit P, et al. 3D image based customized versus standard treatment planning for cervical cancer high dose rate brachytherapy with tandem and ovoids. *J Nucl Med Radiat Ther*. 2015;6:239.
56. National Cancer Institute. Concurrent chemoradiation for cervical cancer. clinical announcement. Washington DC: NCI. 1999.
57. Strauss HG, et al. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase II study. *Strahlenther Onkol*. 2002;178:378-385.
58. Chandel SS and Jain RK. Evaluation of role of concurrent chemotherapy and brachytherapy in locally advanced cervical cancer patients. *J Cancer Sci Ther*. 2016;8:010-014.
59. Huang Z, et al. Onset time of tumor repopulation for cervical cancer: first evidence from clinical data. *Int J Radiat Oncol Biol Phys*. 2012;84:478-484.
60. Marcial VA and Bosch A. Radiation-induced tumor regression in carcinoma of the uterine cervix: prognostic significance. *Am J Roentgenol Radium Ther Nucl Med*. 1970;108:113-123.
61. Beant SG, et al. National cancer data base analysis of radiation therapy consolidation modality for cervical cancer: The impact of new technological advancements. *Int J Radiat Oncol Biol Phys*. 2014.
62. Sahli N, et al. Cervical cancer: Prognostic and evolution after radiotherapy (results from a single institution). *Gynecol Obstet*. 2016;6:353
63. Zhang T, et al. Down-regulated mir-22 as predictive biomarkers for prognosis of cervical cancer. *J Integr Oncol*. 2015;4:145.
64. Thomakos N, et al. Less radical surgery for fertility preservation in patients with earlystage invasive cervical cancer contemporary problematics. *Gynecol Obstet*. 2013;3:165.

65. Antunes D and Cunha TM. Recurrent cervical cancer: How can radiology be helpful. *OMICS J Radiology*. 2013;2:138.
66. Gonfrier G, et al. Type-specific human papillomavirus testing for the follow-up of women with a typical squamous cells of undetermined significance (ascus) pap smears. *Archives in Cancer Research*. 2015;2:12.
67. Berza N, et al. The influence of adjuvant radiotherapy on ovarian function, menopausal symptoms and quality of sexual life in cervical cancer patients. *International Journal Of Collaborative Research On Internal Medicine & Public Health*. 2013;5:377-385.
68. Kimberley A. HPV knowledge and cervical cancer prevention in women. Thesis submitted to Drexell University. 2009.
69. Han I, et al. Multifractionated high-dose-rate brachytherapy with concomitant daily teletherapy for cervical cancer. *Gynecol Oncol* 1996;63:71-77.
70. Spirtos NM, et al. Laparoscopic radical hysterectomy (type iii) with aortic and pelvic lymphadenectomy in patients with stage i cervical cancer: surgical morbidity and intermediate follow-up. *Am J Obstet-Gynecol*. 2002;187:340-348.
71. Yenen MC, et al. port-site metastasis after laparoscopic extraperitoneal para aortic lymphadenectomy for stage iib squamous cell carcinoma of the cervix. *J Minim Invasive Gynecol* 2009;16:227-230.
72. Zakashansky K, et al. New techniques in radical hysterectomy. *Curr Opin Obstet Gynecol*. 2008;20:14-19.
73. Porchia ML, et al. Different effects of the RNASEL r462q mutation on the risk of developing prostate and cervical cancer in Latin American subjects: a meta-analysis. *J Carcinog Mutagen*. 2015;6:234.
74. Gavrilescu MM, et al. Role of sentinel lymph node in early stage of uterine cervical cancer. *Journal of Surgery*. 2014;10:217-222.
75. Cheng J, et al. Study on the relationship between the structure and functions of anti-human cervical cancer single-chain antibody and the lengths of linkers. *J Proteomics Bioinform*. 2014;S8:004.
76. Chang AJ, et al. Intratumoral heterogeneity of <sup>64</sup>cu-at-sm uptake is a prognostic indicator in patients with cervical cancer. *Omics J Radiology*. 2013;2:130.
77. Bellefqih S, et al. Skin metastasis of cervical cancer: About an unusual case. *J Clin Case Rep*. 2013;3:284.
78. Elumelu TN, et al. Palliative care experience in breast and uterine cervical cancer patients in Ibadan, Nigeria. *J Palliative Care Med*. 2013;3:139.
79. Chen JR and Azodi M. Smaller but better? the effort to shrink surgical scale for selected early stage cervical cancer. *Gynecol Obstet*. 2012;2:e108.
80. Langley G and Mary N. Health seeking behaviours of women with cervical cancer. *J Community Med Health Educ*. 2012;2:170.
81. Huang Z, et al. Characterizing at-risk voxels by using perfusion magnetic resonance imaging for cervical cancer during radiotherapy. *J Cancer Sci Ther*. 2012;4:254-259.
82. Bychkov AV, et al. Postmortem investigations following human immunodeficiency virus infection. 2009;1:28-46.
83. Raval BP, et al. Potent *in vitro* anti-tumor activity of *symplocos racemosa* against leukaemia and cervical cancer. *Electronic Journal of Biology*. 2009;5:89-91.
84. Voltyraki EG, et al. The knowledge of women in a greek province regarding the cervical cancer, its prevention capabilities and the pap test. *Health Science Journal*. 2010;4:101-109.
85. Mahmud A, et al. A population-based study of cervix cancer: incidence, management and outcome in the canadian province of saskatchewan. *ClinOncol*. 2011;23:691-695.
86. Ferlay J, et al. Cancer incidence, mortality and prevalence worldwide, version 1.0.
87. Pecorelli S, et al. Revised FIGO staging for carcinoma of the cervix. *Int J Gynaecol Obstet*. 2009;105:107-110.
88. Allen D and Narayan K. Managing advanced stage cervical cancer. *Clinical Obstetrics and Gynaecology*. 2005;19:591-609.
89. Winter R. Prognostic factors in surgically treated stage Ib-IIb cervical carcinomas with special emphasis on the importance of tumor. *Gynaecologic Oncology*. 2001;82:11-16.
90. Williams GH, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. *Proc Natl Acad Sci USA*. 1998;95:14932-14937.

91. Gage JR, et al. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. *J Virol.* 1990;64:723-730.
92. Lee YY, et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. *Gynecol Oncol.* 2011;120:439-443.
93. Sule ST and Shehu MS. Cervical cancer management in Zaria, Nigeria. *African Journal of Health Sciences.* 2007;14:149-153.
94. Wittet S and Tsu V. Cervical cancer prevention and the millennium development goals. *Bull World Health Organ.* 2008;86:488-490.
95. Walboomers JM, et al. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol.* 1999;89:12-19.
96. Solano MR, et al. Expression of WNT genes in cervical cancer-derived cells: Implication of WNT7A in cell proliferation and migration. *Exp Cell Res.* 2015;335:39-50.
97. Nishioka Y, et al. A relationship between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. *Cancer Lett.* 2003;200:49-55.
98. Yenen MC, et al. Port-site metastasis after laparoscopic extraperitoneal paraaortic lymphadenectomy for stage IIb squamous cell carcinoma of the cervix. *J Minim Invasive Gynecol.* 2009;16:227-230.
99. Buga GA. Cervical cancer awareness and risk factors among female university students. *East Afr Med J.* 1998;75:411-416.
100. Fontoura BM, et al. Viral interactions with the nuclear transport machinery: discovering and disrupting pathways. *IUBMB Life.* 2005;57:65-72.